Atrial fibrillation (AF) is
the most common arrhythmia encountered in clinical practice, accounting for
more than 2 million adults in the United States1 and becoming an
emerging epidemic of cardiovascular disease. Its prevalence is not only related to the presence of heart disease, as
demonstrated in the Framingham Heart Study2, where the lifetime risk
of developing AF in the absence of conditions such as chronic heart failure or
coronary artery disease was 16.5% in men and 15.9% in women.
Credits: Francia Rojas MD; Miguel Valderrábano MD